Table 1. Subjects’ clinical characteristics.
| Group I | Group II | P value | |
|---|---|---|---|
| N = 19 | N = 18 | ||
| Age (year) | 71.6±5.1 | 72.7±4.4 | 0.50 |
| Height (m) | 1.55±0.12 | 1.57±0.12 | 0.58 |
| Weight (kg) | 53.1±10.0 | 54.4±12.5 | 0.75 |
| Sex (male) | 7 (36.8%) | 9 (50.%) | 0.43 |
| Duration of PD (year) | 7 (5–13) | 7.5 (4.25–10.5) | 0.73 |
| H&Y stages | 3 (2–4) | 3 (2–4) | 1.00 |
| MMSE score | 26 (20–28) | 24.5 (20–27.5) | 0.68 |
| UPDRS total score | 55.9±15.0 | 46.7±16.3 | 0.09 |
| UPDRS part II score | 13.7±3.9 | 10.8±5.4 | 0.08 |
| UPDRS part III score | 33.9±11.5 | 27.8±8.9 | 0.09 |
| Levodopa (mg) | 400 (375–450) | 400 (300–400) | 0.22 |
NOTE. Values are mean ± SD, n (%) or median (25–75%)
Abbreviations: H&Y, Hoehn and Yahr; MMSE, Mini-Mental State Examination; UPDRS, Unified Parkinson’s Disease Rating Scale.